C-PC (50 mg/kg) exhibits a therapeutic renal effect against potassium dichromate (PD)-induced kidney injury in Wistar rats. This is achieved through improved renal function, downregulation of oxidative stress and the TLR4/TNF-α/HSP70 inflammatory pathway, as well as modulation of IGF-1. Here, TLR4 is linked to kidney injury.